Roche launches bladder & lung cancer drug in India

NEW DELHI: Pharma company Roche on Wednesday said it has launched monoclonal antibody atezolizumab under the brand name Tecentriq in India for treatment of lung and bladder cancer. Tecentriq has shown to extend survival and improve the quality of life in the approved indications, Roche said in a statement. The product has been approved in India “for two types of cancers: non-small cell lung cancer (NSCLC) and Urothelial Carcinoma, a type of bladder and urinary tract cancer”, it added.